Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Analysis of 30 cases of Malherbe's necrotizing epithelioma evidences that this tumor is not at all rare and that signs of malignant degeneration may be detected in it. Rapid growth of this tumor early makes it a discomfort for the patient and may even result in impairment of the visual function. Therefore only early removal of the tumor is a guarantee against such troubles, malignant degeneration included.
 ...
PMID:[Malherbe's necrotizing epithelioma of the eyelid with malignant degeneration]. 237 42

We present a case of focal hepatic steatosis, presenting with longstanding and poorly defined discomfort. The exploratory methods could not exclude the presence of a tumor mass in the liver; for this reason the patient was submitted to surgery, which allowed the histological diagnosis. We call attention to the existence of this lesion and the convenience of using all the available diagnostic methods to obtain the diagnosis in order to avoid the risks of an unnecessary major surgical procedure.
 ...
PMID:[Focal steatosis of the liver]. 239 Mar 60

Hyperthermic intravesical perfusion therapy using peplomycin (40 micrograms/ml) in distilled water at 43 degrees C as a perfusate was performed for 2 to 3 hours in 18 patients with superficial bladder tumors and 2 with deep bladder tumors. The therapeutic efficacy was determined by cystoscopy, ultrasonography and/or CT scan. Complete and partial tumor regression was obtained in 1 and 3 of the 18 patients, respectively. There was no tumor regression in the 12 patients. Most of the patients studied had bladder discomfort such as irritation, urinary frequency and so on, during and/or after perfusion. None of the patients developed acute pyelonephritis.
 ...
PMID:[Hyperthermic perfusion therapy using peplomycin for bladder cancer]. 241 64

From January 1983 to April 1985 six patients suffering from unresectable pancreatic cancer underwent intraoperative irradiation therapy (IORT) followed by external radiotherapy. All tumors showed T4-stages except one tumor staged as T2N2. From the onset of symptoms to IORT the median time of hospitalization was 26.5 days. After surgery, treatment (external irradiation included) required a median hospitalization period of 43.5 days. Follow up, complications and the terminal hospital stay of the patients who died lead to another median hospitalization period of 30 days. Altogether hospitalization required an average of 90 days which represented 38.5% of the mean life-expectancy of 234 (SE = 57.4) days. 47.3% of the survival time did not show discomfort, in 31.6% there were reversible and in 21.1% irreversible complaints. Therefore, patients suffering from unresectable pancreatic cancer had to pay a heavy price for prolonging life expectancy by IORT and following percutaneous irradiation.
 ...
PMID:[Experiences with intraoperative radiotherapy in inoperable pancreatic carcinoma]. 242 16

Nine adult white men ranging in age from 27 to 76 (mean, 55 years) were treated for primary hepatic lymphoma between 1972 and 1986 at the Memorial Sloan-Kettering Cancer Center. Six patients presented with right upper quadrant or epigastric pain or discomfort, and three patients complained of fatigue and lethargy. Fever and night sweats were evident in two, and two patients had lost weight. One patient was asymptomatic; the liver mass was detected during the work-up for cancer of the prostate. Seven patients on whom computerized tomography was performed all had solitary masses in the liver although in three of them tumor had extended into both lobes as noticed at surgery. One had additional porta hepatic lymph node metastasis. Eight patients underwent an exploratory laparotomy; four had hepatic resection, and four had wedge biopsies of unresectable liver tumor. One patient had a percutaneous needle biopsy of the liver. Eight patients received combination chemotherapy. Six patients are alive, five of whom are in initial complete remission. All three patients who died had persistent or recurrent disease in the liver. The results of therapy and surgery to date in these and in other cases in the literature are encouraging.
 ...
PMID:Primary lymphoma of the liver. 244 37

Primary sarcomas of the liver are rare malignant neoplasms. Only four cases of Malignant fibrous histiocytoma (MFH) of the liver have previously been reported in the literature. The authors report a 64-year-old man of MFH of the liver, complained of epigastric discomfort. Laboratory values revealed raised ESR and positive CRP. An abdominal computed tomographic scan disclosed 7.4 x 7.6 cm low density area in the posterior segment of the right lobe. Selective angiography of the celiac artery revealed hypovascular tumor. The diaphragm was involved in the tumor and right hepatectomy with partial resection of diaphragm was performed. Microscopically, the tumor cells were arranged with a storiform pattern and electron microscopic studies demonstrated fibroblast like cells and histiocyte like cells. Although systemic chemotherapy with ACR, CPM and VCR was performed, he died of peritoneal and pleural dissemination on the 142nd day after.
 ...
PMID:[Malignant fibrous histiocytoma of the liver]. 254 36

We evaluated the method of active specific intralymphatic immunization to treat cancer in 32 patients with various tumor types as part of a broad-based phase I-II evaluation and describe the results of 3 sequential series. In series 1, the patients (n = 13) received 2 or more injections of autologous, cryopreserved, irradiated tumor cells directly into the lymphatic system through the cannulation of a dorsal pedal lymphatic channel. In series 2, the patients (n = 7) received low-dose cyclophosphamide, 300 mg per m2, 3 days before the autologous cell vaccine was administered. Series 3 (12 patients) was similar to series 2 except that the tumor cells were treated with cholesteryl hemisuccinate immediately before irradiation. Patients received from 2 to 6 injections of cells, depending on availability, at 2-week intervals. In all, 91 treatments are evaluated in this study. Clinical responses occurred in 7 of the 32 patients and were seen in all 3 series with about the same frequency. These responses occurred in cases of melanoma, lung cancer, colon cancer, and sarcoma. Regressions occurred in both visceral and subcutaneous sites. There was little toxicity, the chief side effect being local discomfort or inflammation. This experience indicates that active specific intralymphatic immunotherapy is safe, produces antitumor effects, and requires more investigation to increase the frequency and duration of observable tumor regression.
 ...
PMID:Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial. 258 64

Elastofibroma dorsi is a benign soft-tissue tumor characterized by the presence of elastic fibers among a stroma of collagenous and fatty connective tissue. This lesion characteristically is located in the subscapular region; however, it has been infrequently described in other anatomic locations. In the subscapular region, it can be a cause of periscapular pain, discomfort, and loss of range of motion. This paper presents a typical case and a brief review of the literature, concentrating on the clinical aspects of elastofibroma dorsi in addition to recent advances regarding the pathogenesis of this unusual lesion.
 ...
PMID:Elastofibroma dorsi. A case report and review of the literature. 265 48

LOCAs offer significant advantages in certain situations, but in others their advantages are either absent or unproved. On the basis of current knowledge and practice, there is no legal mandate to use these agents. Clear advantages to the use of LOCAs are (a) decreased pain and discomfort in painful examinations (in this regard, however, they are equivalent to dilute HOCAs in intraarterial digital subtraction angiography), (b) decreased myocardial and generalized hemodynamic effects, and (c) decreased osmotic load, perhaps important in infants or severely dehydrated patients. LOCAs may be helpful in examinations of patients with alteration of the blood-brain barrier (major trauma, tumor, or stroke), prior contrast media reactions, and marked anxiety. However, in the following areas, there are, as yet, no clear answers about the use of LOCAs: (a) reduction of overall mortality, (b) reduction of morbidity in elderly patients, and (c) reduction of the risk of nephrotoxicity in patients either with or without specific risk factors such as diabetes mellitus or renal failure.
 ...
PMID:Guidelines for use of low-osmolality contrast agents. 267 4

beta 2-Microglobulin (beta 2M)-derived amyloidosis has become a major concern in long-term hemodialysis patients. Clinical symptomatology is largely restricted to the articular and periarticular sites and in rare cases systemic manifestations have been described. We present a long-term hemodialysis patient, who after 16 years of hemodialysis with regenerated cellulosic membranes not only had a bilateral carpal tunnel syndrome, cystic bone translucencies and humeroscapular periarthritis but also developed two subcutaneous tumors in both gluteal regions, causing discomfort when sitting. Histology, immunohistology and electron microscopy of the tumor from the right side showed that it consisted of beta 2M-derived amyloid with concurrent scattered amyloid infiltration of the overlying skin. This report therefore adds a new clinical manifestation to the symptomatology of this type of amyloid.
 ...
PMID:Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient. 267 45


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>